Pharmacogenomic profiling of variants affecting efficacy and toxicity of anti-infective medicines in a south Asian population from Sri Lanka.

Pharmacogenomic profiling of variants affecting efficacy and toxicity of anti-infective medicines in a south Asian population from Sri Lanka.

Publication date: Feb 01, 2025

Anti-infective medicines are crucial for treating infections, but improper dosing can cause toxicity, resistance and treatment failure. Pharmacogenomics can address genetic variations affecting drug efficacy and safety. Despite the high burden of diseases like TB and HIV in Sri Lanka and South Asia, pharmacogenomic data for these populations are limited. This study aims to fill this gap by investigating pharmacogenomic variants in a South Asian population from Sri Lankan. Pharmacogenomic data on anti-infective medicines were obtained from the PharmGKB database, selecting variants with evidence levels 1 A, 1B, 2 A, and 2B. Sri Lankan genetic data were sourced from an anonymized database of 670 Sri Lankans maintained by the Centre for Genetics and Genomics, Faculty of Medicine, University of Colombo. MAFs were compared between Sri Lankan sub-populations and global data from gnomAD, with statistical significance set at p 

Open Access PDF

Concepts Keywords
Hiv Adult
Lanka Anti-Infective Agents
Medicine Anti-Infective Agents
Pharmacogenomics Anti-infectives
Profiling Arylamine N-Acetyltransferase
Arylamine N-Acetyltransferase
Asian People
Female
Genotype
Glucuronosyltransferase
Glucuronosyltransferase
HIV
Humans
Male
NAT2 protein, human
Pharmacogenetics
Pharmacogenomic Variants
Pharmacogenomics
Polymorphism, Single Nucleotide
South Asia
Sri Lanka
Sri Lanka
Tuberculosis
UGT1A1 enzyme
Voriconazole

Semantics

Type Source Name
disease MESH infections
disease MESH treatment failure
pathway REACTOME Reproduction
disease MESH Infectious Diseases
disease IDO bacteria
disease MESH tuberculosis
pathway KEGG Tuberculosis
disease MESH AIDS
disease IDO immunodeficiency
disease IDO host
pathway REACTOME Metabolism
drug DRUGBANK Voriconazole
drug DRUGBANK Efavirenz
disease IDO country
pathway KEGG Drug metabolism
disease MESH clinical significance
disease MESH drug toxicity
disease MESH genetic disorders
disease MESH cancers
drug DRUGBANK Ademetionine
drug DRUGBANK Warfarin
drug DRUGBANK Isoniazid
disease MESH bile
drug DRUGBANK Atazanavir
disease MESH hyperbilirubinemia
drug DRUGBANK Nevirapine
disease MESH Stevens Johnson Syndrome
drug DRUGBANK Aspartame
drug DRUGBANK Inosine
disease MESH anemia
disease MESH COVID 19
drug DRUGBANK Dexamethasone
drug DRUGBANK Coenzyme M
disease MESH drug induced liver injury
disease MESH hepatitis
disease MESH HIV infection
pathway REACTOME HIV Infection
drug DRUGBANK Ritonavir
disease MESH jaundice
drug DRUGBANK Trestolone
disease MESH aspergillosis
disease MESH candidiasis
disease MESH visual hallucinations
disease IDO protein
drug DRUGBANK Indoleacetic acid
disease MESH Syndrome
disease MESH Fungal Infections
disease MESH invasive fungal infections
drug DRUGBANK Thiocolchicoside
pathway REACTOME Acetylation
disease MESH co infection
drug DRUGBANK Guanosine

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *